Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib vs Midostaurin in FLT3 Mutated AML
NCT03836209Phase 2Completed
- Sponsor
- PrECOG
- Start
- Dec 2019
- Primary completion
- Oct 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gilteritinib in acute myeloid leukemia (AML) (2 arms), sponsored by PrECOG. Primary endpoint: FLT3 Mutation Negative Composite Complete Response at 3 months. Started Dec 2019; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03836209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836209.